# Scan Batch E — Steps 5-9 — 2026-09-16

Tickers: STJ.L, CBOE, BMY, AMGN, ICE (all CONFIRMED, technical+fundamental support)

Macro overlay applied to all five: Stagflation regime CONFIRMED today, Fed hiked 25bp to 3.75-4.00% with hawkish dot plot, 10Y UST >5% first time since 2007, Minsky fragility 6/7 (High, escalated today). None of these five sit in a macro-flagged short sector (Financials/Healthcare not named) — treated as general risk-off/late-cycle backdrop, not a name-specific headwind.

Portfolio context: Account ~€74,000. 1/5 position slots occupied (DVN, Energy, €947/1.3%). 4/5 free. Active sizing tier = GOOD (3%, €2,220 max) — confirmed live from data/sentiment_data.json (F&G 28.5, composite 54.5, VIX 17.2). Medium conviction caps at GOOD regardless (matches active tier here, no extra cap needed). Sector cap = 2/sector.

**CROSS-TICKER FLAG: this batch alone contains 3 Financial Services names (STJ.L, CBOE, ICE) against a 2-per-sector cap.** Flagged on each; final pick of which 2 (if any pass other checks) deferred to central reconciliation. Healthcare (BMY, AMGN) = exactly 2, fills the cap with no room for further healthcare adds this session.

**CROSS-TICKER FLAG: R:R hard-minimum (1.5:1 per RISK.md) is violated by STJ.L (1.05), CBOE (1.28) and ICE (1.04).** These three carry entry/stop/target levels computed by the scan pipeline that do not clear the minimum reward:risk threshold regardless of conviction, fundamentals, or institutional read. This drove REJECT on all three below.

---

## STJ.L — St James's Place (UK wealth manager, Financial Services) — High conviction, reversal

### Step 5 — Market Researcher

**1. News Catalysts** — Mixed, recovery-in-progress
- H1 2026 results: EPS £0.60 (up from £0.52 1H25); revenue £21.6bn (+213% YoY, reclassification-driven not organic); net income £310.7m (+11%); profit margin fell to 1.4% from 4.1%
- Client redress programme: aiming to complete all client reviews in 2026; revised ongoing-service redress methodology released £84.5m pre-tax (£63.4m after tax), returned to shareholders via additional buyback
- Net inflows £2.7bn H1 2026, down from £3.8bn prior year — outflows rising in absolute terms, client money "mobile in a competitive market" [UNCONFIRMED precise outflow figure]
- Dividend payment scheduled 18-Sep-2026, yield 1.7% (below sector avg 3.3%) — mechanical, not a directional catalyst
- Macro: BoE/gilt yield environment — no idiosyncratic Fed linkage; UK-domestic name

**2. Sentiment & Narrative** — Mixed/split
- Analyst views split: some lifting targets to £18.70–£20.00 range; at least one cut to Equal Weight; a "fair value" estimate cited around £16.47 vs current price £11.245 (1124.5p) — if directionally correct, implies significant undervaluation, but treat as [UNCONFIRMED] single-source estimate
- Short interest: [NO DATA]
- Narrative: mixed — redress overhang fading (bullish) vs decelerating net inflows (bearish)

**3. Institutional & Options Activity** — [NO DATA]
- No 13F applicability (UK-listed); no options flow data available for this session — [NO DATA]

**4. Sector Rotation Signals** — Soft/mixed
- EU Insurance proxy (EXH5.DE): rank 4/12, ret_5d −0.78%, ret_1m +0.31%, above MA50 — mild
- FTSE100: ret_5d −1.42%, ret_1m −0.86%, above MA200 but below MA50 — soft market backdrop
- US XLF (loose read-across): rank 5/11, ret_5d −0.79%, ret_1m −2.42%, below MA50 — headwind

**5. Market Structure Summary** — Deeply oversold, downtrend
- Trend: down (live snapshot). Price 1124.5, well below MA50 (1146.5) and MA200 (1260.2), far below 52w high (1575.3)
- RSI 24.3 — deeply oversold
- Support 1105 / Resistance 1180 (2% risk zone to support, 5% to resistance)
- Volume ratio 2.72× — elevated, consistent with a capitulation/reversal-candidate day

**6. Upcoming Risk Events**
- No earnings within 7-day lookahead (data/earnings_calendar.json)
- Dividend ex-date 18-Sep (2 days out) — mechanical, immaterial to thesis
- Ongoing regulatory/redress process continues through 2026 — background risk, not a dated event

### Step 6 — Alt Data Agent
```
ALT DATA VERDICT — STJ.L — 2026-09-16
Alt Data Score    : 43  |  Signal: NEUTRAL  |  Flags: none
Insider           : SINGLE_BUY (Bourke, Evelyn: +$33,376) — NEGLIGIBLE impact vs float/volume
Insider MSPR      : UNAVAILABLE
Short Interest    : UNKNOWN — DATA_THIN (EU ticker; insider/short data via yfinance sparse — per rule, absence ≠ bearish)
Analyst Trend      : NO_DATA
News Sentiment    : 0.603 POSITIVE, velocity FALLING, 5 articles (5d) — DATA_THIN caveat for EU coverage
Interpretation    : Thin alt-data coverage typical of EU names; the one live signal (positive but fading news sentiment) roughly matches the mixed analyst narrative — no strong alt-data edge either way.
```

### Step 7 — Strategy Analyst
```
STRATEGY VERDICT — STJ.L — 2026-09-16
Direction: LONG | Strategy: TURNAROUND | Holding: Weeks to months | Timeframe: Daily reversal at support, weekly downtrend
Entry: 1124.5 (current) | Method: Reversal at support / Wyckoff-style spring candidate | Timing: next session open or on confirmation candle
Stop: 1071.5489 — structural, below 1105 support (−4.7%) | Target: 1180 — prior resistance (+4.9%) | R:R: 1.05 [FAILS 1.5 min]
Add at: no add pre-thesis-confirmation | Trim at: +1R → breakeven, then trail | Trail from: 50 SMA recovery (+25%), 200 SMA recovery (+25%)
Hold while: redress process on track, RSI basing, no new guidance cut
Exit if: new structural low below 1071.5; earnings miss/guidance cut; redress costs re-escalate
Max hold: 2 earnings cycles without visible recovery
Thesis: RSI-24 capitulation at support with a specific recovery catalyst (redress programme winding down in 2026, capital returned via buyback) and a fundamentally CONFIRMED Fair rating.
Main Risk: R:R (1.05) is structurally too thin for the stop risk taken — target level under-compensates; decelerating net inflows could extend the downtrend past support.
Earnings Risk: CLEAR (none in 7-day window; next report date unconfirmed beyond that)
```

### Step 8 — Institutional Flow (per-ticker only)
```
INSTITUTIONAL VERDICT — STJ.L — 2026-09-16
Smart Money Score : 45  |  Alignment: CAUTIOUS
13F/ESMA          : DATA UNAVAILABLE (EU ticker — no ESMA large-shareholder filing data sourced this session) — scored NEUTRAL default (+15)
Dark Pool         : DATA UNAVAILABLE — NEUTRAL default (+10)
Options Flow      : DATA UNAVAILABLE — NEUTRAL default (+10)
Sector ETF        : EU Insurance/UK Financials proxy — soft (ret_5d −0.78%, below FTSE MA50) — HEADWIND (+0)
Dry Powder        : DATA UNAVAILABLE (no FMS/Goldman leverage read sourced) — NEUTRAL default (+5)
PROCEED / WAIT / STAND DOWN: WAIT
Reason: Genuine institutional data (13F equivalent, dark pool, options, dry powder) unavailable for this EU name this session; only real signal (sector ETF) is soft — score kept CAUTIOUS by default per inviolable no-fabrication rule.
```

### Step 9 — Risk Manager
**VERDICT: REJECT**
- Position Size: OK — GOOD tier active (3%, €2,220 cap); High conviction, GOOD is the active ceiling anyway
- Portfolio Exposure: WARNING — 1 of 3 Financial Services candidates in this batch vs 2-per-sector cap; provisional, central reconciliation decides which 2 of {STJ.L, CBOE, ICE} survive
- R:R Ratio: FAIL — 1.05 vs RISK.md minimum 1.5:1
- Drawdown Status: OK — no limits approached (only DVN open, 1.3% of account)
- Stop-Loss: OK — 4.7% from entry, below structural support (1105)
- Volatility Context: OK by the letter (VIX 17.2, not against sector trend) — but note general stagflation/Minsky-6/7 backdrop argues for reduced standard sizing if this were otherwise approvable
- **Exact rule violated: RISK.md minimum R:R of 1.5:1 — STJ.L computes to 1.05. No override permitted for conviction level or fundamental quality.**

---

## CBOE — Cboe Global Markets (exchange/derivatives, Financial Services) — Medium conviction, pullback

### Step 5 — Market Researcher

**1. News Catalysts** — Positive operationally
- Raised quarterly dividend 19% to $0.86/share (Aug 13) — 16th straight year of increases
- July 2026 volumes: multi-listed options ADV +28.4% YoY, index options ADV +34% YoY; on track for 7th consecutive record year in US options volume
- Presenting at Barclays Global Financial Services Conference Sep 16 (today)
- Next earnings Oct 30, 2026 (outside hold window relevance for now) — CLEAR of near-term earnings risk

**2. Sentiment & Narrative** — Mixed/Hold
- Consensus rating: Hold (3 Strong Buy / 12 Hold / 3 Strong Sell of 18 analysts) — average PT $317 (range $258–$356)
- Narrative: operationally strong (record volumes, dividend hikes) but analyst base is lukewarm — valuation/growth debate, not a fundamental red flag

**3. Institutional & Options Activity** — [NO DATA] beyond alt-data cross-check
- Alt-data flags INSIDER_MSPR_BEARISH (3-month MSPR −44.6) and one insider sale ($261k) in last 30 days — modest caution, not disqualifying alone

**4. Sector Rotation Signals** — Headwind
- XLF (Financials): rank 5/11, ret_5d −0.79%, ret_1m −2.42%, below MA50 — sector underperforming broad market today (Fed-hike day)
- CBOE/ICE structural bull case (rate hike + volatility → higher exchange trading volumes) is **directionally supported by the volume data above** (record options ADV, record ADV growth), but the sector ETF itself is not showing net inflow today — the tailwind is idiosyncratic to CBOE's own volumes, not yet a broad Financials rotation

**5. Market Structure Summary** — ⚠ Live price has broken through the stated entry
- **Critical finding: live market_data.json shows CBOE at $270.44, change_pct −4.94% today — already ~5% BELOW the stated entry (284.5) and closing in on the stop (264.56).** RSI has fallen to 26.0 (oversold). Price is now below both MA50 (288.63) and MA200 (284.83) — the "up" trend classification from the original scan is no longer clearly supported by live data.
- Support 270.05 / Resistance 309.18 (live levels) — current price is sitting almost exactly on today's live support
- This is a same-day structural deterioration, not a data error — the setup as originally scanned (pullback entry at 284.5) has already been invalidated by price action; a fresh pullback-support test is forming closer to 270

**6. Upcoming Risk Events**
- Earnings Oct 30, 2026 — outside any SWING/EVENT-relevant window
- Today is a Fed decision day — CBOE is name-favorable in principle (vol → options volume) but the stock itself sold off hard alongside broader Financials

### Step 6 — Alt Data Agent
```
ALT DATA VERDICT — CBOE — 2026-09-16
Alt Data Score    : 49  |  Signal: NEUTRAL  |  Flags: INSIDER_MSPR_BEARISH
Insider           : NONE (cluster) / net SELL $261,376 (1 seller, 30d) — mild caution, not disqualifying alone
Insider MSPR      : BEARISH (−44.6, 3mo avg) — net insider selling trend over the quarter
Short Interest    : 2.98% of float, DTC 2.9d — LOW, no headwind, no squeeze setup
Analyst Trend      : STABLE (40.0% bull-rated, Δ0.0pp)
News Sentiment    : 0.852 POSITIVE, velocity STABLE, only 1 article scored (5d) — low article count, low confidence
Interpretation    : Mildly negative undertone (bearish MSPR trend + insider sale) offsetting otherwise clean short-interest/analyst picture — nothing alarming, but not a supportive alt-data tailwind either.
```

### Step 7 — Strategy Analyst
```
STRATEGY VERDICT — CBOE — 2026-09-16
Direction: LONG | Strategy: SWING | Holding: 5–15 days | Timeframe: Daily — Weinstein stage currently indeterminate (price sits below both MA50/MA200 live; original "up" trend classification now stale)
Entry: 284.5 as scanned — INVALID as of live price ($270.44, already through this level); requires re-anchoring to a fresh pullback zone near live support (~270) before entry is actionable
Stop: 264.5634 (7.0% from original entry — exceeds 5% swing max) | Target: 310.08 | R:R: 1.28 [FAILS 1.5 min]
Add at: No add — setup structurally compromised until re-confirmed | Trim at: +1.5R | Trail from: +1R → breakeven
Hold while: price reclaims and holds above today's support (270) with volume confirmation
Exit if: close below 264.56; Impulse System turns Red; 10 sessions no progress
Max hold: 15 trading days
Thesis: CBOE's own trading-volume growth (record options ADV, dividend hikes) offers a name-specific case independent of the broader Financials sector, at a name-specific pullback.
Main Risk: The pullback has already run ~5% past the scanned entry intraday — this is either a much better entry (if it holds) or a broken setup (if support at 270 fails); as scanned, R:R and stop-width both fail RISK.md.
Earnings Risk: CLEAR (Oct 30 report, well outside hold window)
```

### Step 8 — Institutional Flow (per-ticker only)
```
INSTITUTIONAL VERDICT — CBOE — 2026-09-16
Smart Money Score : 40  |  Alignment: CAUTIOUS (lower bound)
13F                : DATA UNAVAILABLE — NEUTRAL default (+15)
Dark Pool          : DATA UNAVAILABLE — NEUTRAL default (+10)
Options Flow       : DATA UNAVAILABLE (ironic given CBOE IS the options exchange — no sweep/flow data sourced this session) — NEUTRAL default (+10)
Sector ETF         : XLF — HEADWIND (ret_5d −0.79%, below MA50) (+0)
Dry Powder         : DATA UNAVAILABLE — NEUTRAL default (+5)
PROCEED / WAIT / STAND DOWN: WAIT
Reason: No 13F/dark-pool/options data sourced this session; only real evidenced signal (sector ETF) is a headwind; alt-data MSPR bearish adds a mild corroborating negative. Score kept at the low end of CAUTIOUS.
```

### Step 9 — Risk Manager
**VERDICT: REJECT**
- Position Size: OK (GOOD tier cap applies, Medium conviction confirmed capped at GOOD)
- Portfolio Exposure: WARNING — 2 of 3 Financial Services candidates in this batch vs 2-per-sector cap
- R:R Ratio: FAIL — 1.28 vs 1.5:1 minimum
- Drawdown Status: OK
- Stop-Loss: WARNING — 7.0% from stated entry, exceeds 5% swing-trade maximum
- Volatility Context: ELEVATED — trade is effectively already against its own setup: live price has traded ~5% through the stated entry same-day, and the original "up" trend read is no longer supported by live MAs
- **Exact rule violated: RISK.md minimum R:R (1.28 < 1.5), compounded by stop distance breach (7.0% > 5% swing cap) and a same-day price move that invalidates the entry level as scanned. Do not execute at the stated entry; would require a fresh scan re-run before any reconsideration.**

---

## BMY — Bristol-Myers Squibb (pharma, Healthcare) — Medium conviction, pullback

### Step 5 — Market Researcher

**1. News Catalysts** — Mildly positive pipeline newsflow
- Priority Review for Camzyos label extension to adolescents (obstructive HCM) — FDA decision targeted by Sep 30, 2026
- EHA Congress 2026: mezigdomide Phase III met primary endpoint in multiple myeloma; early Phase I arlocabtagene autoleucel (CAR-T) showed 96% ORR with manageable safety
- Ongoing: long-term psoriasis study data, bladder-cancer trial (Opdivo) readout
- HSBC maintained rating, lifted PT to $65.00 (from below current-ish level, mild positive)

**2. Sentiment & Narrative** — Mildly bullish, pipeline-driven
- No downgrades found; incremental positive trial data across multiple programmes
- Narrative: steady, not euphoric — large-cap pharma "grinding higher on pipeline proof points"

**3. Institutional & Options Activity** — [NO DATA] — no 13F/dark pool/options data sourced this session

**4. Sector Rotation Signals** — Mild tailwind
- XLV (Healthcare): rank 3/11 today, ret_5d +0.32%, ret_1m −0.43%, above MA50 — best-performing cyclical-ish sector on a day of broad weakness (only XLC and XLE rank higher)

**5. Market Structure Summary** — [DATA LIMITED — BMY not present in this session's market_data.json snapshot]
- Using scan-provided levels only: entry 64.1, stop 61.50, target 68.24, ATR-target 3.18×. Live cross-check price ranges (from search): $63.15–$64.13 on Sep 15, consistent with entry zone (64.1) — no evidence of a same-day breach unlike CBOE
- f_score 57.4 Fair — CONFIRMED per scan flag

**6. Upcoming Risk Events**
- No earnings within 7-day lookahead
- FDA Camzyos decision (~Sep 30) falls inside a plausible SWING hold window — WATCH, not DANGER (label-extension decision, not a pivotal approval — lower binary risk than a first approval)

### Step 6 — Alt Data Agent
```
ALT DATA VERDICT — BMY — 2026-09-16
Alt Data Score    : 50 (default)  |  Signal: NEUTRAL  |  Flags: DATA_UNAVAILABLE
BMY is not present in this session's data/alt_data.json (212 tickers covered, BMY not among them this run).
Per fallback: no fabricated signals. Score defaults to 50/NEUTRAL. Recommend running alt_data.py with BMY included for next session.
[Qualitative, unscored, web-sourced only]: no insider-selling headlines found; HSBC PT raise is the only directionally relevant item, and it is not an alt-data source.
```

### Step 7 — Strategy Analyst
```
STRATEGY VERDICT — BMY — 2026-09-16
Direction: LONG | Strategy: SWING | Holding: 5–15 days | Timeframe: Daily — Weinstein stage not independently verifiable this session (no live market_data.json entry); default to SWING per inviolable rule
Entry: 64.1 — pullback to rising MA/support | Method: MA bounce / pullback | Timing: 10:00–11:30 or 14:30–15:30 window
Stop: 61.4986 (−4.1%) — below nearest support | Target: 68.24 (+6.5%) — Bulkowski/resistance | R:R: 1.59 [MARGINAL — acceptable, not ideal]
Add at: no add | Trim at: +1.5R (target zone) | Trail from: +1R → breakeven
Hold while: pipeline newsflow stays neutral/positive, no guidance cut
Exit if: close below 61.50; Impulse turns Red; Camzyos decision (~Sep 30) resolves adversely — reassess within 1-2 days
Max hold: 15 trading days
Thesis: Multiple positive pipeline readouts (mezigdomide Phase III hit, CAR-T early data) plus a favorable Healthcare sector backdrop support a pullback-buy in a CONFIRMED Fair-rated large-cap pharma name.
Main Risk: FDA Camzyos label-extension decision lands inside the hold window — a negative outcome (unlikely for a label extension, but possible) would be a same-day gap risk.
Earnings Risk: CLEAR in the 7-day lookahead; confirm next full quarterly date before entry given ~5-15 day hold
```

### Step 8 — Institutional Flow (per-ticker only)
```
INSTITUTIONAL VERDICT — BMY — 2026-09-16
Smart Money Score : 55  |  Alignment: CAUTIOUS
13F                : DATA UNAVAILABLE — NEUTRAL default (+15)
Dark Pool          : DATA UNAVAILABLE — NEUTRAL default (+10)
Options Flow       : DATA UNAVAILABLE — NEUTRAL default (+10)
Sector ETF         : XLV — TAILWIND (rank 3/11, ret_5d +0.32%, above MA50) (+10)
Dry Powder         : DATA UNAVAILABLE — NEUTRAL default (+5)
PROCEED / WAIT / STAND DOWN: WAIT
Reason: No granular institutional flow data sourced; the one real, evidenced signal (Healthcare sector ETF strength on an otherwise weak macro day) is the sole positive input, keeping the score CAUTIOUS rather than higher.
```

### Step 9 — Risk Manager
**VERDICT: APPROVE**
- Position Size: OK — GOOD tier (3%, €2,220 cap); Medium conviction correctly capped at GOOD (matches active tier)
- Portfolio Exposure: OK — Healthcare sector, 1st of 2 allowed slots (AMGN is the 2nd candidate in this same batch — both fit within the 2-per-sector cap if both proceed)
- R:R Ratio: MARGINAL — 1.59, above the 1.5 minimum but below the preferred 2.0
- Drawdown Status: OK
- Stop-Loss: OK — 4.1% from entry, within 5% swing max, logically placed below support
- Volatility Context: OK — VIX 17.2 not elevated, trade aligned with a sector showing relative strength; note general stagflation/Minsky-6/7 backdrop as a reason to consider trimming size modestly (e.g. ~2.5% instead of full 3% GOOD-tier max) even though no explicit rule forces this
- No rule violated. Approve at GOOD tier sizing; consider a small discretionary size trim given today's macro fragility escalation, and watch the Sep 30 Camzyos decision inside the hold window.

---

## AMGN — Amgen (biotech, Healthcare) — Medium conviction, pullback

### Step 5 — Market Researcher

**1. News Catalysts** — Mixed, real negative developments present
- FDA approved update to IMDELLTRA prescribing info, substantially reducing required monitoring time — modest positive, commercial-ease catalyst
- **Sector-wide plunge Sep 8, 2026: AMGN closed $397.77 after a broad biotech sell-off, following a ~10% drop tied to a competitor's failed trial read-across** — not company-specific but material to recent price action
- **UK MHRA suspended use/sale of Amgen's rare-disease drug Tavneos to new patients, citing the supporting study as unreliable** — regulatory setback, company-specific
- Phase 3 DeLLphi-305 met its primary endpoint (positive); Repatha plaque-trial data presented, drew investor attention [UNCONFIRMED directional read]

**2. Sentiment & Narrative** — Mixed, recent downgrade
- **HSBC downgraded AMGN to Hold from Buy, PT cut to $425 from $445**
- Wells Fargo raised PT to $435 from $400 but kept Equal Weight (still not bullish)
- Narrative: mixed-to-cautious — real regulatory and competitive-read-across risk alongside genuine pipeline wins

**3. Institutional & Options Activity** — [NO DATA] sourced this session

**4. Sector Rotation Signals** — Sector tailwind, but idiosyncratic headwinds offset it
- XLV: rank 3/11, ret_5d +0.32%, above MA50 — sector itself constructive
- But AMGN-specific news (Tavneos suspension, HSBC downgrade, post-sell-off RSI 17.8) means the sector tailwind is not translating to the stock this week

**5. Market Structure Summary** — Deeply oversold, trend sideways
- Live price 375.65 (below stated entry 381.5, ~1.5% gap — smaller than CBOE's but notable), RSI 17.79 — extremely oversold
- Trend: sideways (live), price below MA50 (397.94) but above MA200 (355.79) — mixed structure, Weinstein stage not cleanly determinable
- Support 375.15 / Resistance 445.82 (wide range, distance to resistance 18.7%)
- ATR% 2.89%, volume ratio ~1.0 (in line with average, no capitulation volume spike despite the earlier Sep 8 sector plunge)

**6. Upcoming Risk Events**
- No earnings within 7-day lookahead
- Tavneos regulatory situation is an ongoing overhang, not a single dated event — treat as background risk requiring monitoring

### Step 6 — Alt Data Agent
```
ALT DATA VERDICT — AMGN — 2026-09-16
Alt Data Score    : 50 (default)  |  Signal: NEUTRAL  |  Flags: DATA_UNAVAILABLE
AMGN is not present in this session's data/alt_data.json (212 tickers covered, AMGN not among them this run).
Per fallback: no fabricated signals. Score defaults to 50/NEUTRAL.
[Qualitative, unscored, web-sourced only]: HSBC downgrade (Buy→Hold) and MHRA Tavneos suspension are real negative developments the technical/fundamental screen would not surface — flagged as a critical note for risk-manager below.
```

### Step 7 — Strategy Analyst
```
STRATEGY VERDICT — AMGN — 2026-09-16
Direction: LONG | Strategy: SWING | Holding: 5–15 days | Timeframe: Daily — Weinstein stage mixed/indeterminate (below MA50, above MA200); default to SWING per inviolable rule
Entry: 381.5 as scanned (live price 375.65, ~1.5% below — minor, not a same-day breach like CBOE) | Method: Oversold bounce / pullback | Timing: 10:00–11:30
Stop: 359.8657 (−5.7% from stated entry — exceeds 5% swing max) | Target: 445.82 (+16.9%) | R:R: 2.97 [HIGH QUALITY]
Add at: no add | Trim at: +1.5R | Trail from: +1R → breakeven
Hold while: no further regulatory deterioration, Tavneos situation contained to the single product
Exit if: close below 359.87; new negative regulatory/competitor read-through; Impulse turns Red
Max hold: 15 trading days
Thesis: RSI-17.8 extreme oversold reading plus a strong R:R (2.97) and a favorable Healthcare sector backdrop offer an attractive statistical bounce setup in a CONFIRMED Fair fundamental name.
Main Risk: Two real, current negative catalysts (HSBC downgrade to Hold, MHRA Tavneos suspension) plus a hard-to-verify competitor-linked sector sell-off are all live — this is not a "clean" oversold bounce, it is oversold-for-a-reason.
Earnings Risk: CLEAR in 7-day lookahead
```

### Step 8 — Institutional Flow (per-ticker only)
```
INSTITUTIONAL VERDICT — AMGN — 2026-09-16
Smart Money Score : 45  |  Alignment: CAUTIOUS
13F                : DATA UNAVAILABLE — but real analyst-side signal (HSBC downgrade Buy→Hold) is a genuine negative data point outside the formal 13F/dark-pool framework — scored below strict-neutral to reflect it (+10 instead of +15)
Dark Pool          : DATA UNAVAILABLE — NEUTRAL default (+10)
Options Flow       : DATA UNAVAILABLE — NEUTRAL default (+10)
Sector ETF         : XLV — TAILWIND (+10)
Dry Powder         : DATA UNAVAILABLE — NEUTRAL default (+5)
PROCEED / WAIT / STAND DOWN: WAIT
Reason: Sector tailwind is real but offset by a genuine sell-side downgrade and an unresolved regulatory overhang (Tavneos) — score kept CAUTIOUS, below BMY's healthcare-peer score.
```

### Step 9 — Risk Manager
**VERDICT: CAUTION**
- Position Size: OK — GOOD tier cap, Medium conviction correctly capped
- Portfolio Exposure: OK — Healthcare sector, 2nd of 2 allowed slots (fills the cap alongside BMY; no room for further Healthcare names if both BMY and AMGN proceed)
- R:R Ratio: OK — HIGH QUALITY (2.97)
- Drawdown Status: OK
- Stop-Loss: WARNING — 5.7% from stated entry, exceeds the 5% swing-trade maximum (structurally placed below support, but the % is wide)
- Volatility Context: ELEVATED — real, dated negative catalysts (HSBC downgrade, MHRA Tavneos suspension) are present and not captured by the technical/fundamental scan; this is thesis-relevant risk the earlier pipeline steps would not have seen
- **What needs to change before APPROVE: (1) tighten stop to within 5% of entry (or reduce size to keep dollar risk equivalent), (2) explicit confirmation that Tavneos is immaterial to AMGN's broader revenue base before sizing at full GOOD tier, (3) treat as CAUTION-sized (e.g. 2% instead of 3%) given the stacked idiosyncratic negative catalysts even though the technical R:R is strong.**

---

## ICE — Intercontinental Exchange (exchange operator, Financial Services) — Medium conviction, pullback

### Step 5 — Market Researcher

**1. News Catalysts** — Strong, positive
- **MarketAxess acquisition announced Jul 29, 2026: ~$6B all-cash deal, $167/share, 33% premium** — major strategic catalyst, expands ICE's fixed-income trading footprint
- Dividend ex-date Sep 16 (today), payment Sep 30, yield 1.6% — mechanical
- **Record trading activity: August 2026 ADV +14% YoY, open interest +19% YoY; interest rate futures hit record open interest in early September 2026** — directly consistent with the rate-hike/high-volatility regime being structurally favorable for exchange volumes

**2. Sentiment & Narrative** — Bullish
- Buy consensus (9 analysts, as of Sep 4, 2026), 12-month PT $185.36 (+14.5% from last reference price)
- Narrative: clearly bullish — M&A expansion plus record volumes in a volatile-rate environment

**3. Institutional & Options Activity** — [NO DATA] sourced this session beyond alt-data cross-check
- Alt-data shows heavy net insider SELLING ($5.48M, 6 sellers, 30d) and MSPR BEARISH (−61.3) — a real conflict against the otherwise bullish narrative (flagged explicitly, not averaged away, per alt-data-agent rules)

**4. Sector Rotation Signals** — Mixed: sector-wide headwind, name-specific tailwind
- XLF: rank 5/11, ret_5d −0.79%, below MA50 — sector headwind
- **This is the case referenced in the task's exchange-operator hypothesis: today's Fed hike / hawkish regime is structurally supportive of ICE's own trading volumes (confirmed by the record-ADV data above), even though the broad Financials ETF is not showing net inflow today.** Treat as name-specific tailwind embedded in a soft sector, not a sector-wide rotation confirmation.

**5. Market Structure Summary** — Constructive, uptrend intact
- Live price 156.9, close to stated entry (157.75, ~0.5% gap, no CBOE-style breach)
- Price above both MA50 (151.49) and MA200 (154.71) — cleaner Stage-2-like structure than the other two Financials names
- RSI 40.1 — neutral, not oversold, consistent with a shallow pullback in an uptrend
- Support 154.95 / Resistance 164.66

**6. Upcoming Risk Events**
- No earnings within 7-day lookahead
- MarketAxess deal close timeline is a background catalyst/risk (regulatory approval risk), not dated within the near-term hold window

### Step 6 — Alt Data Agent
```
ALT DATA VERDICT — ICE — 2026-09-16
Alt Data Score    : 48  |  Signal: NEUTRAL  |  Flags: INSIDER_SELLING, INSIDER_MSPR_BEARISH, NEWS_ACCELERATING
Insider           : SELLING — 6 sellers, $5,477,717 net sold, 30d — caution, not disqualifying alone per rules, but notable size
Insider MSPR      : BEARISH (−61.3, 3mo avg) — corroborates the 30d selling with a longer-run distribution trend, not just noise
Short Interest    : 1.07% of float, DTC 1.5d — LOW; MoM change −32.5% (shorts covering) — mild bullish corroboration
Analyst Trend      : STABLE (90.0% bull-rated, Δ+0.5pp) — very strong absolute buy-rating level
News Sentiment    : 0.581 POSITIVE, velocity RISING, 8 articles (5d) — narrative momentum building (MarketAxess deal driving coverage)
Interpretation    : Genuine tension — strong analyst buy-rating (90%) and rising positive news flow (M&A-driven) vs sustained, sizeable insider selling and bearish MSPR trend. Read as: management/insiders taking profits into strength while the Street stays bullish on the M&A/volume story — not a thesis-breaker, but worth flagging explicitly rather than averaging away.
```

### Step 7 — Strategy Analyst
```
STRATEGY VERDICT — ICE — 2026-09-16
Direction: LONG | Strategy: POSITION | Holding: 4–8 weeks | Timeframe: Daily pullback within an intact uptrend, price above both MA50 and MA200
Entry: 157.75 (live 156.9, ~0.5% gap — actionable) | Method: Pullback to rising MA / throwback | Timing: first hour or intraday pullback to pivot zone
Stop: 151.1157 (−4.2%) — below MA50/near support | Target: 164.66 (+4.4%) — near-term resistance | R:R: 1.04 [FAILS 1.5 min]
Add at: first throwback to breakout level (up to 50% add) | Trim at: +2R take 25% off | Trail from: +1R → breakeven
Hold while: price holds above rising MA50/MA200, MarketAxess deal progresses without regulatory setback
Exit if: weekly close below rising 30-week MA; MarketAxess deal blocked/terminated; insider selling accelerates further with a negative fundamental catalyst
Max hold: 8 weeks
Thesis: Cleanest technical structure of the three Financials names (price above both key MAs), a genuine M&A growth catalyst (MarketAxess), record trading volumes directly consistent with the rate-hike regime, and a 90%-bull analyst base.
Main Risk: R:R (1.04) is the same structural problem as STJ.L/CBOE — the stated target (164.66, near-term resistance) is too close to entry relative to the stop distance; also, sustained insider selling ($5.5M) + bearish MSPR is a real conflicting signal against an otherwise strong tape.
Earnings Risk: CLEAR (no report in 7-day lookahead)
```

### Step 8 — Institutional Flow (per-ticker only)
```
INSTITUTIONAL VERDICT — ICE — 2026-09-16
Smart Money Score : 55  |  Alignment: CAUTIOUS
13F                : DATA UNAVAILABLE formally, but strong analyst-consensus proxy (90% bull-rated, Buy consensus, M&A catalyst) — scored above strict-neutral to reflect it (+25 instead of +15)
Dark Pool          : DATA UNAVAILABLE — NEUTRAL default (+10)
Options Flow       : DATA UNAVAILABLE — NEUTRAL default (+10)
Sector ETF         : XLF — HEADWIND at the sector level (+0), offset narratively by ICE's own record-ADV data (not part of the formal ETF-flow score)
Dry Powder         : DATA UNAVAILABLE — NEUTRAL default (+5)
PROCEED / WAIT / STAND DOWN: WAIT
Reason: Strongest qualitative institutional-adjacent read of the batch (analyst consensus, M&A catalyst, record volumes) but the sustained insider selling ($5.5M net, MSPR −61.3) and lack of genuine 13F/dark-pool/options data keep this at CAUTIOUS rather than ALIGNED — the insider conflict must be explicitly carried to risk-manager per alt-data-agent integration rules.
```

### Step 9 — Risk Manager
**VERDICT: REJECT**
- Position Size: OK — GOOD tier cap; Medium conviction correctly capped at GOOD
- Portfolio Exposure: WARNING — 3rd of 3 Financial Services candidates in this batch vs 2-per-sector cap; on technical/fundamental/institutional quality this is arguably the strongest of the three Financials names, but it still fails independently on R:R below
- R:R Ratio: FAIL — 1.04 vs 1.5:1 minimum
- Drawdown Status: OK
- Stop-Loss: OK — 4.2% from entry, logically placed
- Volatility Context: OK — trade aligned with sector-specific tailwind (rate/volatility regime favorable for exchange volumes), general macro backdrop noted but not disqualifying on its own
- **Exact rule violated: RISK.md minimum R:R (1.04 < 1.5). Despite the best qualitative setup in the batch (M&A catalyst, record volumes, 90% analyst buy-rating, clean technical structure), the stated target (164.66) is too close to entry relative to the stop — RISK.md does not permit an R:R override for conviction or narrative quality. Note for centralized reconciliation: if the target were reset to a level consistent with the stock's actual resistance/measured-move structure (e.g., closer to the ~174.83 52-week high referenced in market data), R:R would likely clear 1.5 and this would be the strongest APPROVE candidate of the three Financials names — recommend a fresh Step 1-4 re-scan of ICE's target level rather than a permanent reject.**
